Table 3.

Changes in metabolic and anthropometric parameters by the administration of empagliflozin.

Variables	Before	After	P-value
BMI, kg/m2	26.6 ± 4.17	25.9 ± 4.00	<0.001a
Body weight, kg	73.0 ± 15.3	71.2 ± 14.8	<0.001a
BMI ≥25 kg/m2 (n = 11)	83.6 ± 10.8	81.4 ± 10.6	<0.001a
BMI <25 kg/m2 (n = 9)	60.0 ± 7.9	58.8 ± 7.9	<0.001a
Body fat mass, kg	24.1 ± 8.24	23.1 ± 7.44	0.0072a
Body skeletal muscle mass, kg	27.0 ± 5.97	26.5 ± 6.32	0.0082a
Systolic blood pressure, mmHg	126 ± 29.7	116 ± 27.5	0.0078a
Diastolic blood pressure, mmHg	77.7 ± 21.8	74.2 ± 24.6	0.14
FPG, mmol/L	10.4 ± 2.64	6.62 ± 1.38	<0.001a
BMI ≥25 kg/m2 (n = 11)	10.8 ± 2.64	6.75 ± 1.14	0.0010a
BMI <25 kg/m2 (n = 9)	9.98 ± 2.73	6.46 ± 1.69	0.0039a
Aspartate transaminase, IU/L	39.6 ± 38.9	27.8 ± 19.9	0.56
Alanine transaminase, IU/L	37.5 ± 66.1	33.5 ± 39.9	0.4
Uric acid, μmol/L	343 ± 101	334 ± 95	0.59
HDL-cholesterol, mmol/L	1.17 ± 0.25	1.12 ± 0.26	0.65
Triglyceride, mmol/L	1.73 ± 0.76	1.29 ± 0.52	<0.001a
LDL-cholesterol, mmol/L	3.19 ± 0.90	3.05 ± 1.11	0.2
Urinary glucose excretion, g/day	24.5 ± 35.1	79.4 ± 35.8	<0.001a
Glucose infusion rate, mg/kg/min	3.71 ± 1.58	4.80 ±1.52	0.0036a
log (glucose infusion rate) (n = 20)	0.53 ± 0.37	0.66 ± 0.27	0.0031a
BMI ≥25 kg/m2 (n = 11)	0.46 ± 0.17	0.63 ± 0.10	0.011a
BMI <25 kg/m2 (n = 9)	0.62 ± 0.17	0.69 ± 0.18	0.15
s.d. value in plasma glucose profiles	2.75 ± 0.8	2.46 ± 0.9	0.20

Values are presented as means ± s.d.

Analysis using paired t-test. Values in bold ^a indicate P < 0.05.

FPG, fasting plasma glucose; HDL, high-density lipoprotein; LDL, low-density lipoprotein.